GlassScriptPhysician profile
Anil S Vedula
NPI 1841527710
$74,167.88
in general payments reported to CMS, 2019-2025
34 companies · $9,314 in 2025
The $9,314 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,749 · 2020: $3,963 · 2021: $3,214 · 2022: $13K · 2023: $14K · 2024: $28K · 2025: $9,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $14K · Food and Beverage: $13K · Travel and Lodging: $568 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,735.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,000.00 |
| Food and Beverage | $12,875.98 |
| Travel and Lodging | $568.05 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $48,919.59 | 2019-2025 | |
| Alcon Vision LLC | $6,153.30 | 2019-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Alcon Research LLC | $4,525.88 | 2019-2024 | |
| Abbvie INC. | $2,213.46 | 2022-2025 | Lumigan, Alphagan P, Durysta |
| Sight Sciences, INC. | $1,805.83 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| New World Medical,INC. | $1,764.96 | 2023-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Allergan, INC. | $1,578.75 | 2019-2022 | |
| Carl Zeiss Meditec, INC. | $1,465.04 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $942.58 | 2019-2025 | Tecnis Iol, Catalys System, Tecnis Iol |
| Bausch & Lomb Americas INC. | $737.46 | 2023-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Glaukos Corporation | $710.52 | 2019-2025 | Photrexa Viscous and Photrexa, Idosetr, Idose |
| Sun Pharmaceutical Industries INC. | $675.59 | 2019-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $487.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $476.81 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $275.05 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $260.79 | 2021 | |
| Dompe US, INC. | $257.62 | 2021-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $110.64 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $99.49 | 2024-2025 | Acthar |
| Topcon Healthcare, INC. | $85.47 | 2019 | |
| Oyster Point Pharma, INC. | $84.93 | 2023-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $83.02 | 2024-2025 | Vevye |
| Amgen INC. | $69.40 | 2024-2025 | Tepezza, Uplizna |
| Eyevance Pharmaceuticals LLC | $65.28 | 2019-2022 | |
| Heru, INC. | $48.69 | 2023 | Heru Hmd |
| Rayner Intraocular Lenses Limited | $47.84 | 2025 | Omidria |
| Genentech USA, INC. | $42.43 | 2022-2023 | Vabysmo |
| Kala Pharmaceuticals, INC. | $40.53 | 2019-2021 | |
| Rxsight INC | $34.35 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Thea Pharma INC. | $30.54 | 2025 | Iyuzeh |
| Regeneron Healthcare Solutions, INC. | $22.36 | 2022 | |
| Akorn, INC. | $21.90 | 2020 | |
| Shire North American Group INC | $16.34 | 2019 | |
| Astellas Pharma US INC | $13.93 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Vedula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.